{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:03:32Z","timestamp":1792213412242,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic reprogramming is a well-known hallmark of cancer. Systematical identification of clinically relevant metabolic subtypes of Hepatocellular carcinoma (HCC) is critical to understand tumor heterogeneity and develop efficient treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an integrative analysis of genomic, transcriptomic, and clinical data from an HCC patient cohort in The Cancer Genome Atlas (TCGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four metabolic subtypes were defined: mHCC1, mHHC2, mHCC3, and mHCC4. These subtypes had distinct differences in mutations profiles, activities of metabolic pathways, prognostic metabolism genes, and immune features. The mHCC1 was associated with poorest outcome and was characterized by extensive metabolic alterations, abundant immune infiltration, and increased expression of immunosuppressive checkpoints. The mHHC2 displayed lowest metabolic alteration level and was associated with most significant improvement in overall survival in response to high CD8+ T cell infiltration. The mHHC3 was a \u201ccold-tumor\u201d with low immune infiltration and few metabolic alterations. The mHCC4 presented a medium degree of metabolic alteration and high CTNNB1 mutation rate. Based on our HCC classification and in vitro study, we identified palmitoyl-protein thioesterase 1 (PPT1) was a specific prognostic gene and therapeutic target for mHCC1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlighted mechanistic differences among metabolic subtypes and identified potential therapeutic targets for subtype-specific treatment strategies targeting unique metabolic vulnerabilities. The immune heterogeneities across metabolic subtypes may help further clarify the association between metabolism and immune environment and guide the development of novel strategies through targeting both unique metabolic vulnerabilities and immunosuppressive triggers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1076587","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:31:35Z","timestamp":1678933895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiabin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangtang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21161","article-title":"Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma","volume":"62","author":"Maluccio","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (Resorce): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase ii safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for hcc: Additional analyses from the phase iii resorce trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.045","article-title":"Recent advances in hepatocellular carcinoma treatment","volume":"19","author":"Parikh","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00568-5","article-title":"Neutrophils as potential therapeutic targets in hepatocellular carcinoma","volume":"19","author":"Geh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: Looking forward","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the warburg effect supports aggressiveness and drug resistance of cancer cells","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist Update"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.017","article-title":"Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - a systematic review and network meta-analysis of 3024 participants","volume":"115","author":"Tan","year":"2018","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (Keynote-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatol (Baltimore Md)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: A review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2017.09.019","article-title":"The liver","volume":"27","author":"Trefts","year":"2017","journal-title":"Curr Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7512159","article-title":"Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities","volume":"2018","author":"De Matteis","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13045-021-01195-y","article-title":"Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma","volume":"14","author":"Liao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1038\/s41467-022-29960-8","article-title":"Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.11.004","article-title":"Altered cancer metabolism in mechanisms of immunotherapy resistance","volume":"195","author":"Ramapriyan","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0263-6","article-title":"Competitive glucose metabolism as a target to boost bladder cancer immunotherapy","volume":"17","author":"Afonso","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell rna sequencing shows the immunosuppressive landscape and tumor heterogeneity of hbv-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41467-020-20171-7","article-title":"Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma","volume":"12","author":"Nguyen","year":"2021","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv428","article-title":"Dendextend: An r package for visualizing, adjusting and comparing trees of hierarchical clustering","volume":"31","author":"Galili","year":"2015","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5555\/1953048.2078195","article-title":"Scikit-learn: Machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"Gsva: Gene set variation analysis for microarray and rna-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3509","article-title":"A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations","volume":"24","author":"Tamborero","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1020","article-title":"Tisch: A comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment","volume":"49","author":"Sun","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.36995","article-title":"Mir-93 regulates vascular smooth muscle cell proliferation, and neointimal formation through targeting Mfn2","volume":"15","author":"Feng","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-022-03893-6","article-title":"Immune effects of Pi3k\/Akt\/Hif-1alpha-Regulated glycolysis in polymorphonuclear neutrophils during sepsis","volume":"26","author":"Pan","year":"2022","journal-title":"Crit Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0305-9","article-title":"Glucose transporter 1 critically controls microglial activation through facilitating glycolysis","volume":"14","author":"Wang","year":"2019","journal-title":"Mol Neurodegener"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56490","article-title":"Zeb1 enhances warburg effect to facilitate tumorigenesis and metastasis of hcc by transcriptionally activating pfkm","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12772","article-title":"Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review","volume":"53","author":"Hu","year":"2020","journal-title":"Cell Prolif"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c130024","article-title":"Energy metabolism in the liver","volume":"4","author":"Rui","year":"2014","journal-title":"Compr Physiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0032-5","article-title":"Targeting metabolism to regulate immune responses in autoimmunity and cancer","volume":"18","author":"Patel","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"Kegg: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn615","article-title":"Amigo: Online access to ontology and annotation data","volume":"25","author":"Carbon","year":"2009","journal-title":"Bioinformatics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0706","article-title":"Ppt1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer","volume":"9","author":"Rebecca","year":"2019","journal-title":"Cancer Discovery"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0741","article-title":"A unified approach to targeting the lysosome's degradative and growth signaling roles","volume":"7","author":"Rebecca","year":"2017","journal-title":"Cancer Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2017.1381804","article-title":"Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of Hk2 (Hexokinase 2)","volume":"14","author":"Jiao","year":"2018","journal-title":"Autophagy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325150","article-title":"Fstl1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of Pkm2","volume":"71","author":"Rao","year":"2022","journal-title":"Gut"},{"key":"B49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0089-3","article-title":"Metabolic aspects in nafld, Nash and hepatocellular carcinoma: The role of Pgc1 coactivators","volume":"16","author":"Piccinin","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/cancers12010068","article-title":"Tca cycle rewiring as emerging metabolic signature of hepatocellular carcinoma","volume":"12","author":"Todisco","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/cancers10110447","article-title":"Lipid metabolic reprogramming in hepatocellular carcinoma","volume":"10","author":"Nakagawa","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.10.045","article-title":"Stratification of hepatocellular carcinoma patients based on acetate utilization","volume":"13","author":"Bj\u00f6rnson","year":"2015","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: How does it benefit cancer cells","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i45.9933","article-title":"Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects","volume":"22","author":"Shang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0244-7","article-title":"The lysosome as a cellular centre for signalling, metabolism and quality control","volume":"21","author":"Lawrence","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/tra.12617","article-title":"Lysosome: The metabolic signaling hub","volume":"20","author":"Lamming","year":"2019","journal-title":"Traffic"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32888","article-title":"Regulation of immune cell metabolism by cancer cell oncogenic mutations","volume":"147","author":"Madi","year":"2020","journal-title":"Int J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0617","article-title":"Microenvironmental metabolism regulates antitumor immunity","volume":"79","author":"Ngwa","year":"2019","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00018.2019","article-title":"Immunity, hypoxia, and metabolism-the m\u00e9nage \u00e0 trois of cancer: Implications for immunotherapy","volume":"100","author":"Riera-Domingo","year":"2020","journal-title":"Physiol Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for Cd4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"Ldha-associated lactic acid production blunts tumor immunosurveillance by T and nk cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3778","article-title":"Immune exclusion-Wnt\/Ctnnb1 class predicts resistance to immunotherapies in hcc","volume":"25","author":"Pinyol","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of hbv-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/biom6020026","article-title":"A bitter sweet symphony: Immune responses to altered O-glycan epitopes in cancer","volume":"6","author":"Cornelissen","year":"2016","journal-title":"Biomolecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1076587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:31:40Z","timestamp":1678933900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1076587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2023.1076587"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1076587","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1076587"}}